Kimberly-Clark to Acquire Tylenol Maker Kenvue in Major Deal

Kimberly-Clark has announced plans to purchase Kenvue, the producer of Tylenol, in a deal valued at around $48.7 billion, positioning itself as a leading force in the consumer health products sector.

Under the terms of the agreement, Kimberly-Clark shareholders will hold about 54% of the new entity, while Kenvue shareholders will take ownership of around 46%.

This merger will combine a wide array of well-known brands, with Kenvue’s products like Listerine and Band-Aids joining Kimberly-Clark’s offerings, which include Cottonelle toilet paper, Huggies diapers, and Kleenex tissues. Together, they will have annual revenues close to $32 billion.

Kenvue, which has only recently existed independently after being spun off from Johnson & Johnson two years ago, gained attention last month when Secretary of Health and Human Services Robert F. Kennedy Jr. brought up the disputed theory linking Tylenol to autism, suggesting that detractors of the idea might have biases against former President Donald Trump.

Kenvue’s CEO, Thibault Mongon, will be stepping down amid pressure from activist investors, with board member Kirk Perry stepping in as interim CEO.

Mike Hsu, the Chairman and CEO of Kimberly-Clark, expressed the company’s commitment to serving consumers across various life stages, indicating he will lead the combined organization.

The headquarters will remain in Irving, Texas, while keeping a significant operation at Kenvue’s site. This acquisition, one of the year’s largest, is still pending approval from shareholders of both companies and is anticipated to finalize in the latter half of next year.

Upon closing, Kenvue shareholders are set to receive $3.50 in cash per share and 0.14625 shares of Kimberly-Clark stock for each Kenvue share they hold. Based on Kimberly-Clark’s recent stock price, this offer is equivalent to approximately $21.01 per share.

Both companies are aiming for cost savings of about $1.9 billion over the initial three years following the deal’s completion. Following the announcement, Kimberly-Clark’s stock saw a dip of over 15%, while Kenvue’s stock experienced a rise of more than 20%.